Immuneering Corp (IMRX)
Immuneering Corp is a biotechnology company focused on oncology. The company is developing IMM-1-104, also known as atebimetinib, a dual MEK inhibitor currently being studied in a Phase 3 trial for certain cancers linked to RAS or RAF mutations, including pancreatic cancer and non-small cell lung cancer. It is also advancing IMM-6-415, or envometinib, in an early-stage Phase 1/2a study in solid tumors, alongside additional deep cyclic inhibitor discovery programs. Immuneering has clinical supply agreements with Regeneron Pharmaceuticals and Eli Lilly and Company to evaluate atebimetinib in combination studies for specific non-small cell lung cancer patient groups. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMRX
|
$5.89
|
32.9% Upside
|
Undervalued
|
$18.86
|
325.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-5.3x
|
1.4x
|
—
|
277.6 M
|
92.019 M
|
1.3%
|
76.1%
|
18.1
|
—
|
91.7%
|
